Protagonist Therapeutics (PTGX) Research & Development (2015 - 2026)

Protagonist Therapeutics has disclosed Research & Development across 12 years of filings, most recently posting $46.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $46.7 million, up 30.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.1 million (up 21.28% YoY), and the FY2025 annual result was $159.3 million, up 15.32% from the prior year.
• Research & Development came in at $46.7 million for Q1 2026 at Protagonist Therapeutics, up from $46.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $46.7 million in Q1 2026 to a low of $25.4 million in Q3 2022.
• The 5-year median for Research & Development is $34.6 million (2022), against an average of $34.7 million.
• Peak annual rise in Research & Development reached 49.8% in 2022, while the deepest fall reached 31.26% in 2022.
• Protagonist Therapeutics' Research & Development stood at $29.9 million in 2022, then dropped by 3.3% to $28.9 million in 2023, then rose by 20.78% to $34.9 million in 2024, then jumped by 32.82% to $46.4 million in 2025, then advanced by 0.82% to $46.7 million in 2026.
• The last three Research & Development figures came in at $46.7 million (Q1 2026), $46.4 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.